Form 8-K - Current report:
SEC Accession No. 0001558370-25-001679
Filing Date
2025-02-27
Accepted
2025-02-27 07:17:50
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20250227x8k.htm   iXBRL 8-K 40816
2 EX-99.1 acrs-20250227xex99d1.htm EX-99.1 222875
3 GRAPHIC acrs-20250227xex99d1001.jpg GRAPHIC 5588
  Complete submission text file 0001558370-25-001679.txt   406728

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20250227.xsd EX-101.SCH 3425
5 EX-101.LAB acrs-20250227_lab.xml EX-101.LAB 15918
6 EX-101.PRE acrs-20250227_pre.xml EX-101.PRE 10225
17 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250227x8k_htm.xml XML 4840
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 25672990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)